Study: 50% hike in rep-hostile docs

Getting face time with busy physicians is becoming harder for pharma reps every year. The fraction of doctors open to meet reps fell nearly 20% last year—to 58% from 71%—while inaccessible doctors now account for 9% of the total, up from 6% last year—a 50% increase.

The findings come from ZS Associates' AccessMonitor report, which monitors rep-related interactions of more than 500,000 physicians, NPs and other prescribers nationwide and tracks both the planned and completed details of about half the nation's sales reps (more than 41,000).

Even docs who were open to seeing some reps became more selective. That trend made some 8 million planned sales calls nearly impossible to complete. Companies are requiring reps to call on prescribers who either refuse to see any sales people at all or refuse to see reps as often as management wants them to, and it's costing pharma more than $1 billion per year.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.